OptimizeRx Corp

OptimizeRx Corp is a U.S.-based digital healthcare technology company that connects life sciences brands with healthcare professionals and patients through proprietary messaging, audience, and media execution tools. Its platform is built around point-of-care distribution, omnichannel patient outreach, and data-driven audience activation delivered through EHR, ePrescribing, and digital media channels.

14,6 %

67,3 %

4,7 %

+18,8 %

3.04

3.04

— OptimizeRx Corp
%
Audience Development30% Tools that identify and prioritize HCP and patient audiences for targeted campaigns.
Audience Activation and Media Execution45% Messaging and media delivery across EHR, eRx, social, CTV/OTT, and other channels.
Audience Profiling10% Profiler insights used to plan channels, partners, and campaign strategy.
Consumer Omnichannel Solutions15% Patient-facing media execution through digital and addressable media channels.

OptimizeRx sells primarily to pharmaceutical and other life sciences manufacturers that need to reach physicians,...

  • Pharmaceutical manufacturersprimary

    Buy HCP and patient engagement solutions to promote brands, support access, and drive prescribing.

  • Life sciences marketing teamsprimary

    Use audience profiling and media execution tools to plan and run targeted campaigns.

  • Patient support program sponsorssecondary

    Buy affordability, co-pay, and support messaging to improve access and adherence.

  • Consumer health advertiserssecondary

    Use DTC omnichannel tools to reach brand-eligible patients across digital media.

OptimizeRx is headquartered in the United States and serves a predominantly U.S.-based healthcare advertising market...

  • Headquartered in the United States
  • Primary commercial market is U.S. life sciences advertising
  • Technology and systems teams in the U.S. and Croatia
  • Contractors in India, Ukraine, the U.S., and Croatia
  • Operations depend on U.S. healthcare data and channel partners

OptimizeRx is focused on expanding from point-of-care messaging into a broader platform that combines audience...

01
Grow DAAP adoptionshort-term

DAAP uses predictive analytics to target HCPs and patients more precisely and can support higher-value engagements.

02
Expand omnichannel executionmedium-term

Adding consumer media channels broadens the addressable market beyond point-of-care messaging.

03
Shift toward recurring data servicesmedium-term

Subscription-based data services can improve revenue predictability and customer retention.

04
Deepen enterprise customer relationshipsshort-term

Larger multi-brand pharma accounts can support cross-sell and expansion within existing customers.

The business depends on a concentrated base of large pharmaceutical customers and on channel partnerships with EHR and...

high

Customer concentration

A small number of large pharmaceutical customers account for a large share of revenue, so account loss or reduced spend can quickly affect results.

Scope
Top five customers represented about 47% of 2025 revenue
Materiality
high
high

Channel partner dependence

The company relies on EHR and eRx platforms to distribute messages at the point of care, so partner disruption can impair delivery and revenue.

Scope
EHR and eRx contracts
Materiality
high
high

Cybersecurity and data privacy

The platform processes healthcare and patient-related information, making breaches or system failures costly and reputationally damaging.

Scope
Healthcare data, proprietary systems, HIPAA/SOC 2 environment
Materiality
high
medium

Regulatory and advertising restrictions

Pharmaceutical marketing is subject to healthcare, privacy, and promotional rules that can limit campaign design and data use.

Scope
Pharma advertising and patient communications
Materiality
high
medium

Seasonality of pharma marketing spend

Brand marketing budgets are often weighted toward year-end, creating quarter-to-quarter volatility in demand and revenue.

Scope
Fourth-quarter budget concentration
Materiality
medium
Revenue recognition and revenue-share expense
Timing and mix can move quarterly revenue and cost of revenues
Internally developed software capitalization
Impacts reported operating income and intangible assets
Acquired intangibles and goodwill
Can create noncash impairment charges
Stock-based compensation
Affects operating expenses and diluted share count
Deferred tax asset valuation allowance
Can materially affect income tax benefit/expense

: 29/04/2026